Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 19/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2821971 | 0.85 | GRM2 (0.64) | GRM2 | |
| SCHEMBL2848318 | 0.85 | GRM2 (0.58) | GRM2 | |
| SCHEMBL2827527 | 0.84 | GRM2 (0.50) | GRM2 | |
| SCHEMBL8011583 | 0.83 | GRM2 (0.56) | GRM2 | |
| SCHEMBL2828009 | 0.83 | GRM2 (0.56) | GRM2 | |
| SCHEMBL8011588 | 0.83 | GRM2 (0.59) | GRM2 | |
| SCHEMBL3741793 | 0.81 | GRM2 (0.54) | GRM2 | |
| SCHEMBL2824048 | 0.80 | GRM2 (0.66) | GRM2SIRT2SIRT1 | |
| SCHEMBL2822683 | 0.80 | GRM2 (0.64) | GRM2 | |
| SCHEMBL2824514 | 0.80 | GRM2 (0.50) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-11-18 | — | — | US | claimed |
| EP-2244576-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2010-11-03 | — | — | EP | claimed |
| WO-2009094265-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK & CO., INC. (US) | 2009-07-30 | — | — | WO | claimed |
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2244576-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009094265-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK & CO., INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | GRM2, GRM3, GRM1 | GRM2 1/4885SIRT2 1700/4885SIRT1 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.